Clinical Experience With RIST-Based Multimodality Therapy in Relapsed Ewing Sarcoma: A Descriptive Single-center Case Series.

Authors

Mahdi Asleh, Yotam Eshel, Miriam Ben Harosh, Aya Khalaila, Abed Abu Quider, Daniel Levin, Hagit Miskin

Published in

Journal of pediatric hematology/oncology. Sep 28, 2026. Epub Sep 28, 2026.

Abstract

Outcomes for relapsed Ewing sarcoma remain poor. The RIST regimen (rapamycin, irinotecan, dasatinib, temozolomide) provides a targeted biological alternative to standard salvage chemotherapy.
We report 3 patients treated with RIST for relapsed Ewing sarcoma.Results:One patient with measurable disease achieved an early partial response before progressing at 9 months. Two patients received RIST as post-local-therapy consolidation with no evidence of disease, maintaining disease control for 41 and 44 months. Toxicities were manageable and primarily hematologic, without treatment discontinuations.
Prolonged outpatient RIST administration is feasible, and its role as multimodality consolidation warrants further prospective evaluation.

PMID:
42804591
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.